ПРАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ТЕРАПИИ И МОНИТОРИНГУ БОЛЬНЫХ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ ВО ВРЕМЯ ПАНДЕМИИ COVID-19
DOI:
https://doi.org/10.31082/1728-452X-2020-213-214-3-4-53-58Ключевые слова:
системная красная волчанка, COVID-19, терапияАннотация
Клинические проявления коронавирусной инфекции COVID-19 имеют схожую клиническую симптоматику с системной красной волчанкой (СКВ). В данной статье приведена сравнительная диагностика двух данных заболеваний. Также даны практические рекомендации врачам по ведению больных системной красной волчанкой различной степени активности в условиях пандемии коронавирусной инфекции.
Библиографические ссылки
Nassonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiia. [Rheumatology. Clinical guidelines]. Moscow: GEOTAR Media; 2017. 464 p.
World Health Organization Coronavirus disease 2019 (COVID-19) situation report 48, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4
Gross O, Moerer O, Weber M, Huber T, Scheithauer S. COVID-19-associated nephritis: early warning for disease severity and complications? Lancet. 2020 16-22 Маy;395(10236):e87-e88. DOI: 10.1016/S0140-6736(20)31041-2
Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression. Therapy, a Case Report. Iran J Kidney Dis. 2020 May;14(3):239-242
Dhital R, Pandey RK, Poudel DR, Oladunjoye O, Paudel P, Karmacharya P. All-cause hospitalizations and mortality in systemic lupus erythematosus in the US: Results from a national inpatient database. Rheumatol Int. 2020;40(3):393-7
Solovyev SK, Aseeva EA, Popkova TV, et al. Systemic lupus erythematosus: new horizons for diagnosisand therapy. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(1):5-14. (Im Russ.). DOI: 10.14412/1995-4484-2020-5-14
Sawalha AH, Manzi S. Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. Eur J Rheumatol. 2020. DOI: 10.5152/eurjrheum.2020.20055
Wallace DJ. Antimalarial drugs in the treatment of rheumatic diseases, 2020. Available from: https://www. uptodate. com/ contents/ antimalarial drugs in the treatmentof rheumatic- disease? search= hydroxychloroquine& source= search_ result& selectedTitle= 2~ 148& usage_ type= default& display_ rank= 1# H7
Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol. 2018 May;30(3):249–55. DOI: 10.1097/BOR.0000000000000500.
Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral in-fections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–7. DOI: 10.1016/s1473-3099(03)00806-5
Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. DOI: 10.1016/j.ijantimicag.2020.105949
Kim A HJ, Sparks JA, Liew JW, et al. A Rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hy-droxychloroquine for COVID-19. Ann Intern Med. 2020 March 30:M20-1223. DOI: 10.7326/M20-1223
Mok CC. The Jakinibs in systemic lupus erythematosus: progress and pro-spects. Expert Opin Investig Drugs. 2019;28(1):85-92. DOI: 10.1080/13543784.2019.1551358
Psarras A, Emery P. Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. DOI: 10.1093/rheumatology/kew431
Muskardin T LW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14(4):214-28. DOI: 10.1038/nrrheum.2018.31
You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019 Oct;78(10):1441-1443. DOI: 10.1136/annrheumdis-2019-215455
Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-31. DOI: 10.1016/S0140-6736(18)31363-1
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. DOI: 10.1016/S0140-6736(20)30251-8
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31. DOI: 10.1016/S0140-6736(20)30304-4
Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15–32. DOI: 10.1007/s40259-019-00333-w
Williams B, Zhang Yi. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19. Lancet. 2020 30 May-5 June;395(10238):1671-1673. DOI: 10.1016/S0140-6736(20)31131-4
Wan Yu, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-e00128. DOI: 10.1128/JVI.00127-20
Gurwitz D. Angiotensin receptor blockers as tentative SARS-COV-2 therapeutics. Drug Dev Res. 2020;81(5):537-540. DOI: 10.1002/ddr.21656
Askanase AD, Khalili L, Buyon JP. Thoughts on COVID-19 and autoimmune diseases. Lupus Science & Medicine. 2020;7:e000396. DOI: 10.1136/lupus-2020-000396
Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020 Jun;79(6):837-839. DOI: 10.1136/annrheumdis-2020-217566
Загрузки
Опубликован
Выпуск
Раздел
Лицензия
Copyright (c) 2021 Медицина
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
